(Courtesy: Pfizer)
NEW YORK - Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
MORE: Pfizer says its COVID-19 vaccine is safe, strongly protective in kids as young as 12
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
This browser does not support the Video element.
Immunized kids are key to ending coronavirus pandemic, experts say
Dr. Kawsar Talaat, an infectious disease physician and assistant professor with the Johns Hopkins Bloomberg School of Public Health, discusses why kids also need to be vaccinated to end the pandemic.
MORE: Real-world study finds Moderna, Pfizer COVID-19 vaccines 90% effective after 2 doses, CDC says
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
MORE: Biden says 90% of US adults will be eligible for COVID-19 vaccine by April 19